Literature DB >> 10207050

Cumulative effect of phosphorylation of pRB on regulation of E2F activity.

V D Brown1, R A Phillips, B L Gallie.   

Abstract

The product of the retinoblastoma susceptibility gene, pRB, is a nuclear phosphoprotein that controls cell growth by binding to and suppressing the activities of transcription factors such as the E2F family. Transactivation activity is inhibited when E2F is bound to hypophosphorylated pRB and released when pRB is phosphorylated by cyclin-dependent kinases (CDKs). To determine which of 16 potential CDK phosphorylation sites regulated the pRB-E2F interaction, mutant pRB proteins produced by site-directed mutagenesis were tested for the ability to suppress E2F-mediated transcription in a reporter chloramphenicol acetyltransferase assay. Surprisingly, no one CDK site regulated the interaction of pRB with E2F when E2F was bound to DNA. Instead, disruption of transcriptional repression resulted from accumulation of phosphate groups on the RB molecule.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207050      PMCID: PMC84119          DOI: 10.1128/MCB.19.5.3246

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  92 in total

1.  Domains A and B in the Rb pocket interact to form a transcriptional repressor motif.

Authors:  K N Chow; D C Dean
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

Review 2.  RB [corrected] as a modulator of transcription.

Authors:  W R Sellers; W G Kaelin
Journal:  Biochim Biophys Acta       Date:  1996-08-08

Review 3.  E2F and the molecular mechanisms of early cell-cycle control.

Authors:  N B La Thangue
Journal:  Biochem Soc Trans       Date:  1996-02       Impact factor: 5.407

4.  E2F-4 switches from p130 to p107 and pRB in response to cell cycle reentry.

Authors:  K Moberg; M A Starz; J A Lees
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

5.  Degradation of E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus transforming proteins.

Authors:  G Hateboer; R M Kerkhoven; A Shvarts; R Bernards; R L Beijersbergen
Journal:  Genes Dev       Date:  1996-12-01       Impact factor: 11.361

6.  The retinoblastoma gene product protects E2F-1 from degradation by the ubiquitin-proteasome pathway.

Authors:  F Hofmann; F Martelli; D M Livingston; Z Wang
Journal:  Genes Dev       Date:  1996-12-01       Impact factor: 11.361

7.  The Rb family contains a conserved cyclin-dependent-kinase-regulated transcriptional repressor motif.

Authors:  K N Chow; P Starostik; D C Dean
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

8.  Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites.

Authors:  E S Knudsen; J Y Wang
Journal:  J Biol Chem       Date:  1996-04-05       Impact factor: 5.157

9.  Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs.

Authors:  P L Chen; D J Riley; Y Chen; W H Lee
Journal:  Genes Dev       Date:  1996-11-01       Impact factor: 11.361

Review 10.  Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation.

Authors:  A Sidle; C Palaty; P Dirks; O Wiggan; M Kiess; R M Gill; A K Wong; P A Hamel
Journal:  Crit Rev Biochem Mol Biol       Date:  1996-06       Impact factor: 8.250

View more
  50 in total

1.  Regulation of E2F1-dependent gene transcription and apoptosis by the ETS-related transcription factor GABPgamma1.

Authors:  Ludger Hauck; Rudolf G Kaba; Martin Lipp; Rainer Dietz; Rüdiger von Harsdorf
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

2.  Phosphorylation puts the pRb tumor suppressor into shape.

Authors:  Andreas M F Heilmann; Nicholas J Dyson
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

3.  PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells.

Authors:  Gabriel De Leon; Margaret Cavino; Mikilyn D'Angelo; Nancy A Krucher
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

4.  Localization of myosin phosphatase target subunit and its mutants.

Authors:  Yue Wu; Andrea Murányi; Ferenc Erdodi; David J Hartshorne
Journal:  J Muscle Res Cell Motil       Date:  2005-07-01       Impact factor: 2.698

5.  Structures of inactive retinoblastoma protein reveal multiple mechanisms for cell cycle control.

Authors:  Jason R Burke; Greg L Hura; Seth M Rubin
Journal:  Genes Dev       Date:  2012-05-08       Impact factor: 11.361

6.  Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization.

Authors:  Kiyoshi Suzuma; Noriko Takahara; Izumi Suzuma; Keiji Isshiki; Kohjiro Ueki; Michael Leitges; Lloyd Paul Aiello; George L King
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

7.  Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding.

Authors:  Jason R Burke; Alison J Deshong; Jeffrey G Pelton; Seth M Rubin
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

8.  Phosphorylation-dependent and -independent functions of p130 cooperate to evoke a sustained G1 block.

Authors:  K Hansen; T Farkas; J Lukas; K Holm; L Rönnstrand; J Bartek
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

9.  Posttranslational modifications of the retinoblastoma tumor suppressor protein as determinants of function.

Authors:  James I Macdonald; Frederick A Dick
Journal:  Genes Cancer       Date:  2012-11

10.  Discrete phosphorylated retinoblastoma protein isoform expression in mouse tooth development.

Authors:  Weibo Zhang; Betsy Vazquez; Viktoria Andreeva; Daisy Spear; Elizabeth Kong; Philip W Hinds; Pamela C Yelick
Journal:  J Mol Histol       Date:  2012-04-04       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.